Burning Rock Biotech Limited (BNR) Tops Q1 EPS by 13c; Offers Guidance

Burning Rock Biotech Limited (NASDAQ: BNR) reported Q1 EPS of (RMB1.81), RMB0.13 better than the analyst estimate of (RMB1.94). Revenue for the quarter came in at RMB142.52 million versus the consensus estimate of RMB143 million.

2023 Financial Guidance

We reiterate our 2023 full-year revenue guidance of approximately 20% growth over 2022 vs. estimated growth of 20.1% Y/Y.

For earnings history and earnings-related data on Burning Rock Biotech Limited (BNR) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Innovaro (INV) Misses Q2 EPS by 9c